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1Chapter
Laboratory Diagnosis of 
Histoplasmosis: An Update
María J. Buitrago and Clara Valero
Abstract
Early diagnosis of histoplasmosis is essential to establish a suitable antifungal 
therapy and reduce morbidity and mortality rates. However, laboratory diagnosis 
remains challenging due to the low availability of proper methods and the lack 
of clinical suspicion. Conventional diagnosis is still largely used even though 
limitations are well known. Isolating the fungus is time consuming and requires 
manipulation in BSL3 facilities, while direct visualization and histopathology 
techniques show low sensitivity and need skilled personnel. New approaches based 
on the detection of antibodies and antigens have been developed and commercial-
ized last years. Although sensitivity and specificity of these methods is variable, 
antigen detection has been recently listed as an essential diagnostic test for AIDS 
patients due to its excellent performance. DNA detection methods are recognized 
as promising tools but there is still a lack of consensus among laboratories and there 
are not commercial tests available. Not all methods are widely available, thus most 
laboratories combine classical and other tests in order to overcome aforementioned 
limitations. In this chapter, we review the diagnostic pipeline currently available for 
the diagnosis of histoplasmosis in microbiological laboratories, from conventional 
to new developed tests. Most recent approaches are introduced and future perspec-
tives are discussed.
Keywords: histoplasmosis, diagnosis, culture, histopathology, PCR, antigen, 
antibody
1. Introduction
Histoplasmosis is caused by the thermally dimorphic fungi Histoplasma cap-
sulatum and encompasses a broad variety of clinical presentations ranging from 
asymptomatic infections to subacute, acute and chronic pulmonary infections 
[1]. In immunosuppressed patients, especially in HIV positive population, it 
causes a progressive disseminated disease [2]. Mortality rates in AIDS population 
have been reported as 30–50% when treated, and 100% in absence of treatment 
[3]. Although this fungus has a cosmopolitan distribution, there are some areas 
of high endemicity as Ohio and Mississippi basins in North America, several 
countries from Central and South America and different regions in the African 
continent [4–6]. Areas of medium-high endemicity have been reported in China 
and some sporadic cases have been described in other regions of Asia as North 
of India, Thailand and Philippines [7–10]. The rest of the world is considered as 
non-endemic regions and reported cases are described as imported by travelers or 
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immigrants [11]. It has been estimated that about a half million of people acquire 
the infection per year and around 100,000 develop a disseminated disease [3]. 
Certain regions of Brazil and Venezuela have been considered hotspots of the dis-
seminated form of the disease [12]. However, in other regions as the African conti-
nent the incidence is probably underestimated due to lack of studies [6]. Diagnosis 
of histoplasmosis is challenging in both endemic and non-endemic regions due to 
its similarity to other diseases as tuberculosis, usually the first clinical suspicion, 
and the limitations and low availability of diagnostic tools. Consequently, many 
efforts have been recently made with the aim of improving diagnosis and combat 
histoplasmosis [3]. In this chapter, we describe the conventional methods used to 
diagnose histoplasmosis coupled with an update about the new tests available. The 
advantages and limitations of each method are detailed as well as their usefulness 
in the diagnosis regarding the diverse clinical presentations of the disease and their 
availability in the different regions. The need of continuous work on the develop-
ment of new methods to achieve an early diagnosis and reduce histoplasmosis 
morbidity and mortality is also underlined.
2. Conventional diagnostic methods
Conventional diagnostic methods are still widely used for the diagnosis of his-
toplasmosis. The definite diagnosis is based on the isolation of the fungus in culture 
or the visualization of intracellular yeasts in tissues or other clinical samples. Thus, 
despite its known limitations, these methods are very useful and continue to be 
used in many laboratories, especially in low-resources settings.
2.1 Culture
The isolation of H. capsulatum in culture is the gold standard for the diag-
nosis of histoplasmosis. The recovery of the fungus by culture from clinical 
samples (blood culture, bronchoalveolar lavage fluid, etc.) is recognized as the 
criteria for the definition of proven histoplasmosis according to the consensus 
definitions of the European Organization for Research and Treatment of Cancer 
and the Mycoses Study Group Education and Research Consortium (EORTC-
MSGERC) [13].
H. capsulatum is a so-called fastidious fungus since it can take up to 4 weeks 
to grow and requires Biosafety level 3 (BSL-3) containment measures [2]. At 
25–30°C, it grows as a white and cottony mycelium that evolves to brown, repre-
senting the invasive form of the disease. This mycelial form is the most dangerous, 
as spores could be inhaled causing infection. Some laboratory-acquired infections 
have been reported by culture manipulation [14]. Microscopically the mycelial 
form produces the typical tuberculate macroconidia, which are easily identi-
fied (Figure 1A). However, other species as Sepedonium spp., an environmental 
organism that is usually considered as a laboratory contaminant, produce similar 
structures. At 37°C (human body temperature), there is a conversion from the 
mycelial phase to the yeast form, which is the pathogenic form of the disease. 
These yeasts are easily recognized by their thick wall and ovoid form with a narrow 
base at the smaller end (Figure 1B).
The sensitivity of cultures depends on the clinical status of the patient and the 
origin of the sample. Cultures are negative in most cases of asymptomatic and mild 
disease, however they are useful in disseminated and chronic pulmonary histoplas-
mosis, although their sensitivity varies from 50 to 85% [2, 15].
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The main limitation of cultures is the long turnaround time needed to reach 
a definite diagnosis. Moreover, the microscopical observation of the grown 
fungus requires further confirmation by other methods. Molecular identifica-
tion by sequencing the internal transcribed spacer (ITS) region of ribosomal 
DNA is a powerful tool to confirm the presence of H. capsulatum, but extends 
the time response for the diagnosis even more. Alternatively, single-stranded 
DNA probes could also be used to detect the fungus in cultures (AccuProbe, 
Hologic, CA, USA), however the procedure is technically complex and time 
consuming [16]. In last years, matrix-assisted laser desorption/ionization-time 
of flight mass spectrometry (MALDI-ToF MS) has started to be developed for 
the identification of H. capsulatum strains [17–19]. Although reports are still 
scarce, results in this area are promising since the system is able for recognizing 
different varieties (var. capsulatum, var. duboisii) and forms of the pathogen 
(yeast and mold), thus reducing response time and decreasing the risk of 
culture manipulation [19].
Since aforementioned limitations make culture useless for an early diagnosis of 
histoplasmosis, a great effort has been made for developing alternative diagnostic 
methods that could be used alone or in combination with cultures.
2.2 Histopathology and direct visualization
Direct examination of clinical samples or performing histopathological studies 
on tissues to detect yeast after staining with Gomori methenamine silver (GMS) or 
periodic acid-Schiff (PAS), are techniques largely used for the diagnosis of histo-
plasmosis. H. capsulatum could appear as a 2- to 4-μm (var. capsulatum) or 8- to 
15-μm (var. duboisii) oval yeast. As yeasts are phagocytosed by macrophages, they 
could be found forming clusters, which can help the diagnosis. However, several 
fungi can be misled with H. capsulatum such as, among others, the small variant 
of Blastomyces dermatitidis, endospores of Coccidioides spp., Candida glabrata as 
well as the causal agents of leishmaniasis, toxoplasmosis, and Chagas’ disease [20]. 
The higher sensitivity could be obtained in respiratory specimens or bone marrow 
biopsy in patients with disseminated histoplasmosis [21]. However, the low speci-
ficity and the need of skilled personnel to achieve a presumptive diagnosis are the 
main limitations of this technique.
Figure 1. 
Photomicrograph of lactophenol cotton blue stains of both filamentous and yeast forms of H. capsulatum. 
(A) Culture at 30°C on potato dextrose agar (PDA) showing tuberculate macroconidia (63× magnification). 
(B) Culture at 37°C on ML-GEMA medium showing yeasts (20× magnification). Both images belong to the 
image library of the mycology reference laboratory (National Centre of Microbiology, Instituto de Salud 
Carlos III, Madrid, Spain).
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3. Antigen detection
The detection of H. capsulatum antigens in clinical samples represented a 
breakthrough in the early diagnosis of histoplasmosis and has been included in 
the EORTC/MSG criteria for diagnosis of IFIs for almost 20 years [13, 22, 23]. The 
H. capsulatum polysaccharide antigen can be detected in both serum and urine 
samples with similar diagnostic value and has been recently listed as an essential 
diagnostic test for advanced AIDS patients [24, 25]. Two assays based on enzyme 
linked immunosorbent assay (ELISA) have been commercialized with good diag-
nostic performances (Table 1) although their availability is limited.
MiraVista’s test presents great efficiency in serum and urine samples from 
patients with disseminated infection, but it is reduced in patients with pulmonary 
forms of the disease [26], in which BALF samples are more suitable for diagnosis 
[28]. This test is only performed in MVista’s facilities then is not accessible out 
of USA limiting their use. On the other hand, IMMY has recently released an 
Histoplasma GM ELISA test which shows great performance and reproducibility, 
but has only be tested in urine samples [27]. Despite the high degree of cross-
reaction with other fungi, antigen detection assays are widely used to diagnose 
histoplasmosis and some reports indicate its capacity to monitor treatment response 
[29, 30]. Nevertheless, their use is restricted mainly to developed endemic areas but 
it is rarely used in non-endemic regions, probably due to its low cost-effectiveness 
out of endemic regions [24, 31].
In last years, point-of-care (POC) testing has been emerged as a new diagnostic 
methodology and immuno-chromatographic assays performed in lateral-flow 
devices (LFD) are good examples. These “pregnancy tests-like” assays are easy to 
use, have low turnaround time (less than an hour) and require minimal laboratory 
equipment which facilitate its implementation in low- and middle-income countries 
[32, 33]. This technology was first developed for Aspergillus GM detection with 
great results and MVista has recently released a similar test consisting of a dipstick 
sandwich immunochromatographic assay based on the recognition of H. capsulatum 
GM antigen. Although it has only been tested in serum samples from AIDS patients, 
its diagnostic performance was very promising (sensitivity of 96%, specificity  
Testa Samples Methodology Turnaround 
time
Sensitivity/
specificity
Limitations
MV Serum, 
plasma, 
urine, 
CSF, 
BALF, 
other 
body 
fluids
ELISA Urine, BAL: 
<24 h
Serum, 
plasma, CSF: 
24 h
bDH: 92%
APH: 83%
SAPH: 30%
CPH: 88%
• Cross-reactivity 
with other fungi
• Samples are 
required to 
be shipped to 
the company’s 
facilities
IMMY Urine ELISA <2:15H c95-98%/97-98% • Cross-reactivity 
with other fungi
aMV: Histoplasma Quantitative EIA test (MiraVista Diagnostics, Indianapolis, IN, USA); IMMY: CLARUS 
Histoplasma GM EIA kit (IMMY, Norman, OK, USA).
bDH [26].
cIn 95-98% [27].
ELISA: enzyme-linked immunosorbent assay; CSF: cerebrospinal fluid; BALF: bronchoalveolar lavage fluid; DH: 
disseminated histoplasmosis; APH: acute pulmonary histoplasmosis; SAPH: sub-acute pulmonary histoplasmosis; 
CPH: chronic pulmonary histoplamosis; GM: galactomannan.
Table 1. 
Main characteristics and diagnostic performance of commercial assays for detecting H. capsulatum antigens.
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of 90%) [34]. However, false positive and negative results still occurred due to 
cross-reactivity with other endemic fungi and antibiotic treatment, respectively, 
and a pre-treatment step was required extending turnaround times. Currently, a 
new LFD test is being developed and validated by using urine samples [35].
4. Antibody detection
The main advantages of antibody detection tests are the requirement of mini-
mally invasive samples and the achievement of results when culture is still nega-
tive reducing the need of handling potentially infectious fungi [36]. Serological 
techniques such as complement fixation or immunodiffusion are useful when 
testing samples from travelers coming from endemic regions for the first time. Both 
techniques are commercially available (Immuno Mycologics, Norman, OK, USA) 
and the sensitivity of these tests in acute and subacute pulmonary histoplasmosis 
has been reported as 95% [37]. However, sensitivity is very limited in immuno-
suppressed patients due to low or absent antibody titers. A recent meta-analysis 
described sensitivity and specificity values of 58% and 100%, respectively, in 
samples from HIV patients [38]. Finally, since seropositivity remains long time after 
disease, interpretation of serological results could be challenging [39, 40]. Despite 
the limitations previously described, antibody detection tests are still considered as 
valuable diagnostic tools and have been demonstrated to improve diagnostic yield 
when combined with other diagnostic methods [41, 42].
5. DNA based detection methods
PCR methods based on the detection of fungal DNA directly from clinical 
samples are currently implemented in the routine of several laboratories for the 
diagnosis of main fungal infections, but there are considerably fewer PCR tests 
for the diagnosis of histoplasmosis. Their advantages rely on their simplicity, high 
specificity and short turnaround time with the bonus that real-time PCR (qPCR) 
formats allow for determining the fungal burden in patients by using non-specific 
DNA-binding dyes or fluorescently labeled probes [36, 43]. However, this technique 
also has some limitations as the moderate amount of DNA in low invasive samples, 
the lack of standardization and the low availability of widely validated commercial 
systems [44, 45]. Recently, PCR based methods have been included in the EORTC/
MSG criteria for the diagnosis of some fungal infections such as invasive aspergil-
losis or candidiasis but not for endemic mycoses [13].
The majority of PCR tests for the diagnosis of histoplasmosis have been 
developed in house and none of them has been commercialized. They have been 
recently reviewed in several reports with different purposes [31, 38, 46]. Most 
developed methods targeted specific multicopy regions of the ribosomal DNA or 
the single-copy Hcp100 gene and were performed by using conventional, nested or 
qPCR formats. The sensitivity and specificity of these assays depends on the type 
of sample analyzed, the clinical characteristics of patients and the PCR format 
used for DNA detection. These tests showed an excellent analytical performance 
(overall sensitivity of 95% and specificity of 99%) when testing samples of HIV 
patients [38], but sensitivity decreased when testing blood and serum samples 
from immunocompetent patients [31, 46]. Panfungal or broad-range PCRs are 
used when there is not a clear suspicion of the fungus involved in the infec-
tion, since universal primers are used to detect any fungal DNA in the clinical 
sample. Although studies are scarce, several reports achieved the detection of 
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H. capsulatum DNA in clinical samples by using this technique, which could be 
especially useful in non-endemic regions [47–51].
Non-PCR based methods are also able to amplify and detect H. capsulatum DNA 
from clinical samples. Loop-mediated isothermal amplification (LAMP) rests on 
the use of a DNA polymerase with high displacement strand activity and a set of 
specifically designed primers to amplify targeted DNA [52]. Some reports described 
the implementation of this technique for the molecular diagnosis of histoplasmosis 
showing great results [53, 54]. The high efficiency, sensitivity, specificity and cost-
effectiveness of these assays make them good candidates to be implemented in the 
diagnostic routine of resource-limited laboratories.
6. Conclusions and future perspectives
Early diagnosis of histoplasmosis is essential to establish a suitable antifungal 
therapy, which results in the reduction of mortality rates [55, 56]. This becomes 
especially important in certain hyper-endemic regions since they usually are 
disfavored areas where patients develop the disease in its disseminated form. While 
culture and histopathological examination are considered the gold standards 
methods for histoplasmosis diagnosis, these techniques show moderate sensitivity. 
In addition, culture is time consuming, requiring handling fungi in BSL-3 facilities. 
New approaches as MALDI-ToF MS technology allow for a rapid identification, but 
studies are still scarce. Antibody and antigen detection are useful tools for an early 
detection of the pathogen in low invasive clinical samples such as serum and urine. 
Despite limitations concerning sensitivity in certain populations and specificity 
have been widely reported, H. capsulatum antigen detection has been recently 
included in the second edition of the list of essential in vitro diagnostics (https://
www.who.int/medical_devices/diagnostics/selection_in-vitro/selection_in-vitro-
meetings/sage-ivd2nd-meeting/190318-2ndEditionofEDL-open-session.pdf?ua=1). 
Regarding molecular methods, in the last decade a great effort has been made on 
the development of PCR tests for the detection of H. capsulatum DNA in a broad 
spectrum of clinical samples showing excellent diagnostic performance. However, 
a consensus among laboratories about the best samples, targets and procedures is 
mandatory. Consequently, no commercial tests are available to date limiting the 
use of this technique. To date, only an inter-laboratory study focused on molecular 
techniques for the diagnosis of histoplasmosis has been published [57]. In this work, 
authors concluded that qPCR targeting a multicopy genomic region was the best 
option for a suitable sensitivity. A European initiative is being launched to carry out 
multicenter studies in this regard.
All these problems have gained attention thanks to different initiatives coming 
from researchers from hyper-endemic regions [58] or international foundations as 
the Global Action Fund for Fungal Infections (GAFFI). As a result, proposals such 
as the Manaus declaration have been launched, specifically to get access to rapid 
testing for histoplasmosis in the Americas and Caribe until 2025 (https://www.
gaffi.org/the-manaus-declaration-on-histoplasmosis-in-the-americas-and-carib-
bean-100-by-2025/). However, in addition to these excellent initiatives further work 
is required to improve diagnosis. In this sense, novel techniques as next generation 
sequencing (NGS) have been found to be useful in the diagnosis of several infec-
tions. Sequences obtained from clinical samples through NGS can be compared 
against reference databases enabling their identification to the genus and species 
level [59]. This technique has been used recently to identify H. capsulatum as the 
causal agent of a case of chronic meningitis [60] and for the differential diagnosis 
among histoplasmosis, leishmaniosis and talaromycosis [61]. Another approach 
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in constant development is based on determining host and fungal biomarkers that 
could indicate the presence of H. capsulatum in human body fluids. Recent advances 
in antibody detection are related to the refinement of antibody detection platforms 
(Histoplasma antibody IgG IgM EIA, MiraVista Diagnostics), while most efforts in 
antigen detection are focused on improving diagnostic yields of POC methods [35].
In summary, the aim of this chapter was to summarize the diagnostic pipeline 
currently available for the diagnosis of histoplasmosis in microbiological labora-
tories (Figure 2). Although so much progress has been made in the area, much 
certainly remains to be done to improve the early diagnosis of histoplasmosis, 
allowing the establishment of a prompt antifungal therapy and consequently 
reducing morbidity and mortality rates of this infection.
Conflict of interest
The authors declare no conflict of interest.
Figure 2. 
Diagnostic pipeline currently available for the microbiological diagnosis of histoplasmosis. aHistopathological 
preparation showing a H. capsulatum yeast budding [62]. bDirect visualization of fine needle aspiration 
cytology showing intra- and extracellular yeasts of H. capsulatum [63]. MALDI-ToF MS: matrix-assisted laser 
desorption/ionization-fime of flight mass spectrometry; ID: identification; EIA: enzyme immunoassay; LFD: 
lateral flow device; POC: point of care; qPCR: quantitative PCR; NGS: next generation sequencing.
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